JP2007532495A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007532495A5 JP2007532495A5 JP2007506658A JP2007506658A JP2007532495A5 JP 2007532495 A5 JP2007532495 A5 JP 2007532495A5 JP 2007506658 A JP2007506658 A JP 2007506658A JP 2007506658 A JP2007506658 A JP 2007506658A JP 2007532495 A5 JP2007532495 A5 JP 2007532495A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- ghrelin
- individual
- medicament
- thyroiditis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000000580 secretagogue effect Effects 0.000 claims description 7
- 102100033367 Appetite-regulating hormone Human genes 0.000 claims 20
- 239000003814 drug Substances 0.000 claims 16
- 101800001586 Ghrelin Proteins 0.000 claims 15
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 claims 15
- 230000007812 deficiency Effects 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 206010020850 Hyperthyroidism Diseases 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 210000001685 thyroid gland Anatomy 0.000 claims 6
- 101710111255 Appetite-regulating hormone Proteins 0.000 claims 5
- 238000009472 formulation Methods 0.000 claims 5
- 239000003324 growth hormone secretagogue Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 4
- 230000001575 pathological effect Effects 0.000 claims 4
- 206010043778 thyroiditis Diseases 0.000 claims 4
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims 3
- 201000007497 subacute thyroiditis Diseases 0.000 claims 3
- 239000005495 thyroid hormone Substances 0.000 claims 3
- 229940036555 thyroid hormone Drugs 0.000 claims 3
- 208000023328 Basedow disease Diseases 0.000 claims 2
- 208000015023 Graves' disease Diseases 0.000 claims 2
- 206010043784 Thyroiditis subacute Diseases 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- 125000001165 hydrophobic group Chemical group 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 208000007884 postpartum thyroiditis Diseases 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 230000007704 transition Effects 0.000 claims 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- 206010000599 Acromegaly Diseases 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000021738 Plummer disease Diseases 0.000 claims 1
- 206010052649 Primary hypogonadism Diseases 0.000 claims 1
- 206010059594 Secondary hypogonadism Diseases 0.000 claims 1
- 206010044242 Toxic nodular goitre Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 239000003200 antithyroid agent Substances 0.000 claims 1
- 229940043671 antithyroid preparations Drugs 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 210000000748 cardiovascular system Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000002651 drug therapy Methods 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 208000016361 genetic disease Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 201000003368 hypogonadotropic hypogonadism Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 235000012054 meals Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200400569 | 2004-04-07 | ||
| DKPA200401656 | 2004-10-27 | ||
| PCT/DK2005/000237 WO2005097173A2 (en) | 2004-04-07 | 2005-04-07 | Use of ghrelin for the treatment of hyperthyroidism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007532495A JP2007532495A (ja) | 2007-11-15 |
| JP2007532495A5 true JP2007532495A5 (enExample) | 2008-05-08 |
Family
ID=34981499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007506658A Withdrawn JP2007532495A (ja) | 2004-04-07 | 2005-04-07 | グレリン欠乏を治療するための分泌促進薬の使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20080171700A1 (enExample) |
| EP (1) | EP1742655A2 (enExample) |
| JP (1) | JP2007532495A (enExample) |
| CA (1) | CA2603295A1 (enExample) |
| WO (1) | WO2005097173A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006045314A2 (en) * | 2004-10-27 | 2006-05-04 | Gastrotech Pharma A/S | Use of a growth hormone secretatogue for increasing or maintaining lean body mass and/or for treatment of chronic obstructive pulmonary disease |
| KR101510082B1 (ko) * | 2006-08-01 | 2015-04-10 | 더 스크립스 리서치 인스티튜트 | 비만증을 억제하기 위한 백신 및 방법 |
| CA2677045C (en) | 2007-01-31 | 2016-10-18 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| US9371297B2 (en) | 2007-02-09 | 2016-06-21 | Ocera Therapeutics, Inc. | Macrocyclic ghrelin receptor modulators and methods of using the same |
| KR101623985B1 (ko) | 2007-03-28 | 2016-05-25 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 스티칭된 폴리펩티드 |
| RU2548753C2 (ru) | 2009-11-16 | 2015-04-20 | Ипсен Фарма С.А.С. | Фармацевтические композиции лигандов рецепторов меланокортинов |
| CN102821775B (zh) * | 2010-03-15 | 2014-10-22 | 益普生制药股份有限公司 | 生长激素促分泌素受体配体的药物组合物 |
| KR102104762B1 (ko) | 2010-08-13 | 2020-04-24 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티도미메틱 거대고리 |
| CN108929375A (zh) | 2011-10-18 | 2018-12-04 | 爱勒让治疗公司 | 拟肽大环化合物 |
| EP2819688A4 (en) | 2012-02-15 | 2015-10-28 | Aileron Therapeutics Inc | PEPTIDOMIMETIC MACROCYCLES CROSS-LINKED WITH TRIAZOLE AND THIOETHER |
| KR102112373B1 (ko) | 2012-02-15 | 2020-05-18 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방체 마크로사이클 |
| KR20230097201A (ko) * | 2012-09-27 | 2023-06-30 | 아라타나 세라퓨틱스, 인크. | 식욕부진을 조절 화합물 조성물 및 이의 이용 방법 |
| JP6218084B2 (ja) | 2012-10-04 | 2017-10-25 | 国立研究開発法人国立循環器病研究センター | 悪性腫瘍転移抑制用医薬 |
| KR20150082307A (ko) | 2012-11-01 | 2015-07-15 | 에일러론 테라퓨틱스 인코포레이티드 | 이치환 아미노산 및 이의 제조 및 사용 방법 |
| US9750723B2 (en) | 2013-10-31 | 2017-09-05 | Ohio University | Prevention and treatment of non-alcoholic fatty liver disease |
| CN106659714B (zh) | 2014-07-18 | 2021-06-08 | 俄亥俄大学 | 用于改变生物信号传导的咪唑和噻唑组合物 |
| CN106999541A (zh) | 2014-09-24 | 2017-08-01 | 艾瑞朗医疗公司 | 拟肽大环化合物及其用途 |
| MX2017011834A (es) | 2015-03-20 | 2018-04-11 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos y usos de los mismos. |
| EP3781158A4 (en) * | 2018-02-14 | 2022-03-16 | Lumos Pharma, Inc. | Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis |
| CN110859953B (zh) * | 2019-10-26 | 2025-08-12 | 沈阳医学院 | Ghrh-a在制备治疗非酒精性脂肪性肝病药物中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US501403A (en) * | 1893-07-11 | Richard brayton | ||
| US26252A (en) * | 1859-11-29 | Harness-yoke | ||
| US134593A (en) * | 1873-01-07 | Improvement in chair seats and backs | ||
| US48623A (en) * | 1865-07-04 | wilson hodges | ||
| US605853A (en) * | 1898-06-21 | caude | ||
| US305138A (en) * | 1884-09-16 | Sash-fastener | ||
| US403295A (en) * | 1889-05-14 | Machine for coating or impregnating bags with wax | ||
| US192292A (en) * | 1877-06-19 | Improvement in malting of grain | ||
| US1060190A (en) * | 1912-09-20 | 1913-04-29 | Franklin Knitting Mills | Knitted necktie. |
| US1197496A (en) * | 1914-06-30 | 1916-09-05 | Richard Jobling | Expansible pipe and joint. |
| CZ20011309A3 (cs) * | 1998-11-03 | 2001-10-17 | Novo Nordisk A/S | Sloučeniny s vlastnostmi uvolňování růstového hormonu |
| CA2362290A1 (en) * | 1999-02-18 | 2000-08-24 | Kaken Pharmaceutical Co., Ltd. | Novel amide derivatives as growth hormone secretagogues |
| IL147652A0 (en) * | 1999-07-23 | 2002-08-14 | Kangawa Kenji | Novel peptides |
| EP1353683A4 (en) * | 2000-05-30 | 2004-05-12 | Merck & Co Inc | ANALOGS BY GHRELIN |
| ES2383796T3 (es) * | 2001-12-18 | 2012-06-26 | Alizé Pharma SAS | Composiciones farmacéuticas que comprenden grelina no acilada para su utilización en el tratamiento de la resistencia a la insulina |
| EP1407779A1 (en) * | 2002-10-10 | 2004-04-14 | Gastrotech A/S | Use of ghrelin for treating low body weight and body fat in gastrectomized individuals |
| EP1660117A2 (en) * | 2003-08-06 | 2006-05-31 | Gastrotech Pharma A/S | Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite |
-
2005
- 2005-04-07 CA CA002603295A patent/CA2603295A1/en not_active Abandoned
- 2005-04-07 WO PCT/DK2005/000237 patent/WO2005097173A2/en not_active Ceased
- 2005-04-07 EP EP05715155A patent/EP1742655A2/en not_active Withdrawn
- 2005-04-07 US US11/578,135 patent/US20080171700A1/en not_active Abandoned
- 2005-04-07 JP JP2007506658A patent/JP2007532495A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007532495A5 (enExample) | ||
| RU2552324C2 (ru) | Фармацевтические композиции и соответствующие способы доставки | |
| Thorton et al. | Short-and long-term use of octreotide in the treatment of congenital hyperinsulinism | |
| CN1293916C (zh) | 稳定的胰岛素制剂 | |
| US8933023B2 (en) | Rapid acting injectable insulin compositions | |
| US8084420B2 (en) | Rapid acting and long acting insulin combination formulations | |
| Sinko et al. | Biopharmaceutical approaches for developing and assessing oral peptide delivery strategies and systems: in vitro permeability and in vivo oral absorption of salmon calcitonin | |
| JP2021503468A5 (enExample) | ||
| US20120288531A1 (en) | pharmaceutical compositions for delivery of ferric iron compounds, and methods of use thereof | |
| GB2112641A (en) | The use of peptides as medicaments | |
| GB2368792A (en) | Absorption enhancers | |
| US20250170218A1 (en) | Stable pharmaceutical composition of receptor agonist, and preparation method and application thereof | |
| US8664268B2 (en) | Gallium compositions for the treatment of liver cancer and methods of use | |
| KR101639470B1 (ko) | 신경내분비 종양의 치료방법 | |
| Stöckmann et al. | Long-term treatment of patients with endocrine gastrointestinal tumours with the somatostatin analogue SMS 201-995 | |
| Carlsson et al. | The long-acting somatostatin analogue octreotide decreases pancreatic islet blood flow in rats | |
| EP3871692B1 (en) | Pharmaceutical composition with blood sugar lowering effect | |
| Edelman et al. | Quantification of insulin release from implantable polymer‐based delivery systems and augmentation of therapeutic effect with simultaneous release of somatostatin | |
| JP2013501043A5 (enExample) | ||
| JP2013501043A (ja) | 経口投与可能な医薬製剤 | |
| CN1511037A (zh) | 非肠道使用的雌莫司汀磷酸盐和白蛋白的制剂 | |
| CN113509544B (zh) | 一种具有降血糖作用的药物组合物 | |
| CN104998262A (zh) | Dpp4抑制剂在防治辐射诱导骨髓抑制药物中的应用 | |
| Harano et al. | Efficacy of combined insulin and somatostatin infusion for the treatment of experimental diabetic ketoacidosis | |
| CN100384427C (zh) | 一种含活性成分阿德福韦或其盐的经注射给药的制剂及其制备方法 |